RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06517953, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Pathologically confirmed adenocarcinoma of the lung, with locally advanced or metastatic disease and not amenable to curative surgery or radiotherapy (stage IIIB, IIIC or IV disease based on the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification). Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.

    Inclusion criterion 2

    Tissue or blood samples are confirmed by the central laboratory or research center as rare EGFR mutations, including exon 18 G719X, S768I in exon 20 and at least one of the L861Q mutations in exon 21;

    Inclusion criterion 4

  3. Patients must be treatment-naive for locally advanced or metastatic NSCLC systemic antitumor therapy. Prior adjuvant and neo-adjuvant therapy (except for EGFR-TKIs) is permitted if have been completed at least 6 months prior to initiation of disease progression.

    Inclusion criterion 3

    Agree to use effective contraception during the study period and for at least 3 months after completion of the study treatment.

    Inclusion criterion 8

    Previous traditional chinese medicine with an antitumor indication within 2 weeks before the first dose of study drug.

    Exclusion criterion 4

    Previous major surgery within 4 weeks before the first dose of study drug,or planing to have major surgery during study.

    Exclusion criterion 5

    Any unresolved toxicities from prior treatment greater than NCI CTCAE v4.03 grade 2 or higher.

    Exclusion criterion 7

    Previous therapeutic clinical trial within 4 weeks before the first dose of study drug.

    Exclusion criterion 24

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

    Inclusion criterion 5

  5. absolute neutrophil count(ANC)<1,500/mcL

    Exclusion criterion 15

    platelets<100,000/mcL

    Exclusion criterion 16

    hemoglobin<9.0 g/dL

    Exclusion criterion 17

    AST/ALT>2.5 times the upper limit of normal (ULN)or >5 times the ULN in the presence of liver metastases

    Exclusion criterion 18

    total bilirubin(TBIL)>1.5 times the ULN if no liver metastases or > 3 times the ULN in the presence of liver metastases

    Exclusion criterion 19

    serum creatinine(SCr) >1.5 times the ULN or creatinine clearance ≥50 mL/min.

    Exclusion criterion 20

  6. At least 1 measurable tumor lesion without radiotherapy as per RECIST v1.1.

    Inclusion criterion 7

  7. Active infection including hepatitis B,hepatitis C,syphilis and human immunodeficiency virus (HIV).

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06517953, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 18 years of age or older.
  • Pathologically confirmed adenocarcinoma of the lung, with locally advanced or metastatic disease and not amenable to curative surgery or radiotherapy (stage IIIB, IIIC or IV disease based on the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification). Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
  • Patients must be treatment-naive for locally advanced or metastatic NSCLC systemic antitumor therapy. Prior adjuvant and neo-adjuvant therapy (except for EGFR-TKIs) is permitted if have been completed at least 6 months prior to initiation of disease progression.
  • Tissue or blood samples are confirmed by the central laboratory or research center as rare EGFR mutations, including exon 18 G719X, S768I in exon 20 and at least one of the L861Q mutations in exon 21;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • Predicted survival ≥ 3 months.
  • At least 1 measurable tumor lesion without radiotherapy as per RECIST v1.1.
  • Agree to use effective contraception during the study period and for at least 3 months after completion of the study treatment.
  • Provision of informed consent prior to any study procedure.

Exclusion Criteria:

  • Combined with other malignancy(except for clinically cured in situ cervix carcinoma, basal cell or squamous epithelial skin cancer,thyroid papillary carcinoma).
  • Prior treatment with any EGFR-TKIs.
  • Prior treatment with any systemic antitumor therapy for locally advanced or metastatic NSCLC.
  • Previous traditional chinese medicine with an antitumor indication within 2 weeks before the first dose of study drug.
  • Previous major surgery within 4 weeks before the first dose of study drug,or planing to have major surgery during study.
  • Symptoms or signs worsened within 2 weeks before the first dose of study drug.
  • Any unresolved toxicities from prior treatment greater than NCI CTCAE v4.03 grade 2 or higher.
  • Spinal cord compression,symptomatic or unstable central nervous system (CNS) metastases that require the use of steroids .Patients who have a stable CNS status for at least 4 weeks before treatment will be allowed to join the study.
  • Any clinical evidence of serious or uncontrolled systemic disease,including uncontrolled hypertension after drug treatment,active bleeding diatheses, previous or present thrombus,uncontrolled cardiovascular and cerebrovascular diseases.
  • Active infection including hepatitis B,hepatitis C,syphilis and human immunodeficiency virus (HIV).
  • Mean resting corrected QT interval (QTcF) ≥450 msec,obtained from 3 ECGs or any clinically important abnormalities in rhythm,conduction, morphology of resting ECG or left ventricular ejection fraction (LVEF) ≤ 50%,etc.
  • Previous history of interstitial lung disease(ILD),drug-induced interstitial lung disease,history of radiation-induced pneumonia requiring hormone therapy,or clinical evidence of active interstitial lung disease.
  • Any instance that affects the patient's ability to swallow drug or oral malabsorption.
  • Occur any laboratory indicator abnormalities as follow:
  • absolute neutrophil count(ANC)<1,500/mcL
  • platelets<100,000/mcL
  • hemoglobin<9.0 g/dL
  • AST/ALT>2.5 times the upper limit of normal (ULN)or >5 times the ULN in the presence of liver metastases
  • total bilirubin(TBIL)>1.5 times the ULN if no liver metastases or > 3 times the ULN in the presence of liver metastases
  • serum creatinine(SCr) >1.5 times the ULN or creatinine clearance ≥50 mL/min.
  • Patients with a known allergy or delayed hypersensitivity reaction to the any component of study drugs or their excipients.
  • Within 1 week before the first dose of study drug currently receiving or need concomitant medications known to be potent inhibitors or inducers of CYP3A, CYP2D6,CYPC8 and CYP2C19,sensitive substrate of CYP3A and CYP2C9.
  • Within 1 week before the first dose of study drug ongoing use of warfarin.
  • Previous therapeutic clinical trial within 4 weeks before the first dose of study drug.

Quoted from ClinicalTrials.gov, NCT06517953, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06517953, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06517953